In cancer, histone deacetylases (HDACs) are often overexpressed, and HDAC inhibitors can promote hyperacetylation of HSP90, leading to the degradation of c-RAF and Akt—key signaling molecules involved in tumor growth and resistance to MAPK inhibitors in melanoma [96]. This evidence concerns the gene HDAC9 and cancer.